克立硼罗在皮肤科的应用进展  

Application Progress of Crisaborole in Dermatology

作　　者：陈辅琼 郭砚[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院皮肤病与性病科,青海 西宁

出　　处：《临床医学进展》2022年第5期4891-4896,共6页Advances in Clinical Medicine

摘　　要：目的:综述磷酸二酯酶-4抑制剂克立硼罗软膏(Crisaborole)在治疗皮肤性疾病中的研究进展。方法:查阅近5年国内外文献27篇,对其进行归纳、分析和总结。结果:新型磷酸二酯酶-4抑制剂克立硼罗通过抑制磷酸二酯酶-4,增加细胞内cAMP水平,继而减少体内炎症因子的合成,在特应性皮炎、银屑病等炎性皮肤病方面作用显著。目前,克立硼罗已获得中国国家药监局批准,用于2岁以上轻中度特应性皮炎患者的治疗,商品名为舒坦明。结论:克立硼罗软膏作为新型磷酸二酯酶-4抑制剂,在皮肤性疾病中应用广泛,具有良好的发展前景及探究意义。Objective: To review the research progress of phosphodiesterase-4 inhibitor Crisaborole ointment in the treatment of skin diseases. Methods: 27 literatures at home and abroad in recent 5 years were reviewed and summarized. Results: The new phosphodiesterase-4 inhibitor, criboro, in-creased intracellular cAMP level by inhibiting phosphodiesterase-4, thereby reducing the synthesis of inflammatory factors in vivo, and played a significant role in inflammatory skin diseases such as atopic dermatitis and psoriasis. At present, crisaborole has been approved by the State Administra-tion of Drugs of China for the treatment of patients over 2 years old with mild to moderate atopic dermatitis, and the commodity name is Shutanming. Conclusion: Crisaborole ointment, as a new phosphodiesterase-4 inhibitor, is widely used in skin diseases and has good development prospects and exploration significance.

关 键 词：PDE-4抑制剂 克立硼罗软膏 皮肤性疾病 治疗 

分 类 号：R751[医药卫生—皮肤病学与性病学]